Research Papers:

Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer

Kang Liu, Xiao Li, Jie Wang, Yichun Wang, Huiyu Dong and Jie Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:19298-19309. https://doi.org/10.18632/oncotarget.15197

Metrics: PDF 1370 views  |   HTML 2247 views  |   ?  


Kang Liu1,*, Xiao Li2,*, Jie Wang1,*, Yichun Wang1, Huiyu Dong1, Jie Li1,*

1Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

2Department of Urology, The Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China

*These authors contributed equally to this work

Correspondence to:

Jie Li, email: [email protected]

Keywords: genetic variants, RhoA/ROCK1 pathway, prostate cancer, prognosis, biochemical recurrence

Received: July 27, 2016     Accepted: January 03, 2017     Published: February 08, 2017


The contribution of genetic variants in RhoA and ROCK1 genes towards prostate cancer risk has not been reported before. We genotyped six potentially functional genetic variants in a case-control study of 1699 subjects. Overall, we found rs2410 mutant allele and rs2269736 wild allele were risk factors for prostate cancer. Individuals carrying more than two risk alleles were exposed to hazard of prostate cancer. In addition, we demonstrated that the risk of biochemical recurrence might be linked with clinico-pathological characteristics and also genetic factors. Unfortunately, no associations were observed between all polymorphisms and clinico-pathological characteristics. Moreover, no genotype was found as significant independent prognostic predictor for biochemical recurrence survival in Multivariate Cox regression analysis after Bonferroni correction. Our study is the first to clarify the relations of genetic variants of RhoA and ROCK1 genes with development, progression and prognosis of prostate cancer. These variants may be promising novel biomarkers to facilitate clinical treatment decision-making.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15197